Reduced cytomegalovirus reactivation and viremia without increasing GVHD after URD-PBSCT: A prospective study using targeted ATG dosing strategy

• Published in: Cancer pathogenesis and therapy
• Main Authors: Chen, Sheng, Wang, Lu, Luan, Songhua, Wang, Haitao, Du, Jishan, Ge, Dongxue, Li, Fei, Wu, Yongli, Gu, Zhenyang, Dou, Liping, Liu, Daihong
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.04.2025
• Subjects: Anti-thymocyte globulin; Graft-versus-host disease; Unrelated donor hematopoietic stem cell transplantation; Viral reactivation; Anti-thymocyte globulin; Graft-versus-host disease; Unrelated donor hematopoietic stem cell transplantation; Viral reactivation

Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation (allo-HCT) to prevent severe graft-versus-host disease (GVHD) and graft failure. Insufficient ATG exposure may reduce its effectiveness in GVHD prophylaxis, while excessive exposure can elevate the ris...